Journal
WORLD JOURNAL OF HEPATOLOGY
Volume 7, Issue 10, Pages 1377-1389Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4254/wjh.v7.i10.1377
Keywords
Hepatitis C virus; Diagnosis; Treatment; Hepatocellular carcinoma; Nucleic acid test; Enzyme immunoassay; Interferon; Direct acting antivirals; Hosttargeted agents; Sofosbuvir
Categories
Funding
- National Science Council of Taiwan [NSC 101-2320-B-320-011-MY3]
- Tzu Chi University [TCIRP 103002-03, TCIRP 103002-02]
Ask authors/readers for more resources
More than twenty years of study has provided a better understanding of hepatitis C virus (HCV) life cycle, including the general properties of viral RNA and proteins. This effort facilitates the development of sensitive diagnostic tools and effective antiviral treatments. At present, serologic screening test is recommended to perform on individuals in the high risk groups and nucleic acid tests are recommended to confirm the active HCV infections. Quantization and genotyping of HCV RNAs are important to determine the optimal duration of anti-viral therapy and predict the likelihood of response. In the early 2000s, pegylated interferon plus ribavirin became the standard antiHCV treatment. However, this therapy is not ideal. To 2014, boceprevir, telaprevir, simeprevir, sofosbuvir and Harvoni are approved by Food and Drug Administration for the treat of HCV infections. It is likely that the new all-oral, interferon-free, pan-genotyping anti-HCV therapy will be available within the next few years. Majority of HCV infections will be cured by these antiviral treatments. However, not all patients are expected to be cured due to viral resistance and the high cost of antiviral treatments. Thus, an efficient prophylactic vaccine will be the next challenge in the fight against HCV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available